SEOM clinical guidelines for anaplastic gliomas (2017)

• C. Balañá ^[7] ; M. Alonso ^[1] ; A. Hernandez ^[2] ; P. Perez-Segura ^[3] ; E. Pineda ^[8] ; A. Ramos ^[2] ; A. R. Sanchez ^[4] ; P. Teixidor ^[5] ; E. Verger ^[8] ; M. Benavides ^[6]
  1. [1] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  2. [2] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  3. [3] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  4. [4] Complejo Asistencial Universitario de León

     Complejo Asistencial Universitario de León

     León, España

     
  5. [5] Hospital Universitari Germans Trias i Pujol

     Hospital Universitari Germans Trias i Pujol

     Barcelona, España

     
  6. [6] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
  7. [7] Institut Català Oncologia Badalona, España
  8. [8] Hospital Clínic i Provincial Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 1 (January 2018), 2018, págs. 16-21
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnostic/prognostic and predictive value of IDH1/IDH2 missense mutations and 1p/19q codeletions in AG. The diagnosis of anaplastic oligoastrocytoma is discouraged. Surgery, radiotherapy and chemotherapy with PCV or TMZ are the first-line standard of care for AG with slight modifications according to molecular variables. A multidisciplinary team is highly recommended in the management of these tumors.